Top Tweets for #gu24
#SpanielHour
ROCKYS FAMILY ARE WONDERING HOW THEIR DOG VANISHED - he always stayed close 🧐
#Woking #SURREY #GU24
WAS HE STOLEN? PICKED UP & KEPT or STUCK SOMEWHERE?
https://t.co/SBqLoxf2er
@Wokinghamlive @wokingboard @JacquiSaid @MissingPetsGB @millypod1
#GU24 LS22 presented by @DrChoueiri - very interesting data - I predict it will generate a lot of new questions Re activity, tox profile, immature OS data, subsequent treatments etc —> I’m sure @katy_beckermann will help us interpret the data!!
Day 3 #ASCOGU2026 Kidney Camcer
@DrChoueiri presented #LITESPARK02
Pembro +belzutifan significantly improved DFS vs pembro alone in high-risk ccRCC post-nephrectomy (HR 0.72).
Benefit consistent across subgroups.
Key toxicity - anemia
👉 1st adjuvant ph 3 RCC trial to show benefit over an active IO comparator.
OS follow-up ongoing.
@Uromigos @OncoAlert @tompowles1 @brian_rini
LAST DAY!! #GU26 @asco 📅
⏰Awaiting @katy_beckermann discussion of the LITESPARK studies! starting 8:10 am
- Are we going to change treatment sequencing in mRCC? @motzermd
- Is there a new standard for adjuvant ccRCC? @DrChoueiri
Don´t miss this evvent @Larvol @OncoAlert
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers. @sonpavde @AdventHealthCFL @ASCO #GU24 https://t.co/OAIyFCacpy
Renal cancer poll of the day #GU24
KIM1 will be better than IMDC at predicting response to immune therapy in renal cancer @OncoAlert
@DrChoueiri with the results of the ARC-20 trial evaluating the safety and efficacy of castadifan monotherapy in previously treated #ccRCC with promising data #GU24
Next: Phase 3 PEAK-1 trial of Cabozantinib +/- Casdatifan in PD-1 treated #RCC
@ASCO @DanaFarber
Amazing presentation by @VincentWenxinXu #GU24 about the role of KIM-1 as a biomarker to IO therapy in #RCC
@ASCO @DanaFarber
Our very own @VincentWenxinXu taking the stage to discuss his outstanding work on KIM-1 as a biomarker of response to immunotherapy in #RCC
High baseline KIM-1 = Worse outcomes
Early KIM-1 drop on NIVO+IPI = Major survival benefit
3-week >30% decrease ➡️ ORR 69%, mPFS 71 mo, mOS 85 mo!
@ASCO #GU25 @OncoAlert @DanaFarber @DanaFarber_GU @BIDMChealth @BrighamWomens @harvardmed @Clara__Steiner @MarcMachaalani @Uromigos @urotoday @ASCOPost @OncLive @DrYukselUrun @yekeduz_emre
@TiansterZhang with masterful discussion of kry presentations from @AlbigesL @motzermd @katy_beckermann #GU24
Estimados Colegas, un honor presentar a @cdanicas 🇪🇸Platicando de manejo de toxicidad de ADC's con @nataliagandur 🇦🇷 en @asco #GU25
@nataliagandur @bavilima @yekeduz_emre @DrChoueiri @neerajaiims @PGrivasMDPhD @montypal @DrYukselUrun @sonpavde @NazliDizman @ziremozay @Chrislabaki1 @DRBakaloudiMD @nsayeghmd @seanmmcbride @scserendipity1 @weoncologists @ReneeSaliby @MikeSerzanMD @drenriquegrande
Dr. Milowsky #OS outcomes from CheckMate 274 ➡️ adjuvant nivo showed DFS benefit and OS benefit (55.2 mos vs 40.2 mos) over placebo irrespective of prior neoadj chemo in #MIBC after radical surgery @ASCO #GU24
@OncoAlert
ASCO GUからの速報です。オリゴ転移のある前立腺癌に対し、転移巣に対する局所治療（MDT）と標準治療を行うことは標準治療のみに比べて有意に予後を改善することが、臨床試験の患者一人ひとりのデータ（IPD）を用いたX-MET研究のメタ解析で明らかになりました。
#GU24
https://t.co/708WIOzEd1
ASCO GUからの速報です。相同組み換え修復（HRR）遺伝子異常がある転移を有する去勢抵抗性前立腺癌（mCRPC）に対するPARP阻害薬タラゾパリブとエンザルタミドの併用は、プラセボとエンザルタミドの併用よりも死亡のリスクを37.8％低減できることが明らかとなりました
#GU24
https://t.co/oijMbb5O6W
ASCO GUからの速報です。転移を有する去勢抵抗性前立腺癌（mCRPC）に対するPARP阻害薬タラゾパリブとエンザルタミドの併用は、プラセボとエンザルタミドの併用よりも死亡のリスクを20.4％低減できることが明らかとなりました。
#GU24
https://t.co/P9kwiXUDkO
From #GU24 to #GU25, our @CityofHope group has grown from small but mighty to national and even more mighty 💪🏼
🩻Radiographic criteria to assess response by Dr Danny Mena Cortes 👏@dandanmena
@ASCO #GU24
@MikeSerzanMD @ReneeSaliby @yekeduz_emre @ReginaBarCar @crisbergerot @drenriquegrande @bavilima
Thoughtful #ProstateCancer study evaluating sequencing of #PARPi & Abi #GU24
small study (n~20) w/ wide CI’s made smaller w/limited cross over
Highlights path forward for a larger trials perhaps in a cooperative group to definitively answer this necessary❓of combo vs sequence
Stellar presentation from @neerajaiims @huntsmancancer at @ASCO #GU25. Impressive to see the benefit across subsets in #TALAPRO2! Great to see this story build first at #GU24 and now here.
What impresses me most about Neeraj is his ability to lead practice-changing studies while placing equal emphasis and attention on building an amazing team of mentees. Most have won @ConquerCancerFd Merit Awards - they’re sitting right behind me cheering him on!
@ziremozay @ggebraelmd @nsayeghmd @chadihc98
Last Seen Hashtags on Sotwe
momsonn
Seen from United States
恋母
leak #fr
Seen from Netherlands
evanlamicella
Seen from Mexico
minichat() +filter:native_video
Seen from United States
뮤직뱅크마드리드
Seen from United States
ensest duş
Seen from Turkey
teenagersgirls #nolimit
Seen from Mexico
pantspoop
Seen from Thailand
Randomchat filter:videos
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers